现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • D-JNKI-1 (AM-111)
D-JNKI-1 (AM-111)的可视化放大

D-JNKI-1 (AM-111)

D-JNKI-1 (AM-111) (AM-111) 是一种高效且可渗透细胞的 JNK 肽抑制剂。

原价
¥1612-12175
价格
1290-9740
D-JNKI-1 (AM-111)的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajce44356
  • CAS: 1445179-97-4
  • 别名: AM-111; XG-102
  • 分子式: C164H286N66O40
  • 分子量: 3822.44
  • 纯度: >98%
  • 溶解度: Water : ≥ 50 mg/mL (13.08 mM)
  • 储存: Store at -20°C
  • 库存: 现货

Background

D-JNKI-1 is a highly potent and cell-permeable peptide inhibitor of JNK.


D-JNKI-1 (1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells[1].


D-JNKI-1 (10 μM) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner[1]. D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage[2]. D-JNKI-1 (1 μg/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4+ and CD8+ cells in mice[3].


[1]. Wang J, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci. 2003 Sep 17;23(24):8596-607. [2]. Zhao Y, et al. The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria. Mol Cell Neurosci. 2012 Mar;49(3):300-10. [3]. Kersting S, et al. The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium. J Inflamm Res. 2013 May 3;6:71-81. [4]. Wang C, et al. Wu-tou decoction attenuates neuropathic pain via suppressing spinal astrocytic IL-1R1/TRAF6/JNK signaling. Oncotarget. 2017 Oct 6;8(54):92864-92879.

Protocol

Animal experiment:

D-JNKI-1 is dissolved in a 0.9% sodium chloride solution for subcutaneous application. Each group (the 1.0% DSS group and the 1.5% DSS group) is randomly subdivided into an intervention group (n = 15) and a control group (n = 15). The mice in the intervention group receive three subcutaneous nuchal administrations of 1 μg/kg D-JNKI-1 on days 2, 12, and 22. The mice in the control group receive physiological saline subcutaneously as a negative control at the same time points in a comparable stress situation.

参考文献:

[1]. Wang J, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci. 2003 Sep 17;23(24):8596-607.
[2]. Kersting S, et al. The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium. J Inflamm Res. 2013 May 3;6:71-81.
[3]. Zhao Y, et al. The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria. Mol Cell Neurosci. 2012 Mar;49(3):300-10.
[4]. Wang C, et al. Wu-tou decoction attenuates neuropathic pain via suppressing spinal astrocytic IL-1R1/TRAF6/JNK signaling. Oncotarget. 2017 Oct 6;8(54):92864-92879.

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服